Arovella Therapeutics Limited (ASX:ALA)
Australia
· Delayed Price · Currency is AUD 0.0770
-0.0010 (-1.28%)
At close: Mar 6, 2026
Arovella Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Operating Revenue | - | 0.14 | 0.02 | 0.41 | 0.3 | 0.26 | Upgrade
|
| Other Revenue | 3.21 | 3.3 | 1.94 | 1.05 | - | 0.73 | Upgrade
|
| Revenue | 3.21 | 3.44 | 1.95 | 1.45 | 0.3 | 0.99 | Upgrade
|
| Revenue Growth (YoY) | -6.90% | 76.22% | 34.20% | 391.75% | -70.11% | -20.91% | Upgrade
|
| Cost of Revenue | - | - | - | 0.2 | 0.21 | 0.24 | Upgrade
|
| Gross Profit | 3.21 | 3.44 | 1.95 | 1.25 | 0.09 | 0.75 | Upgrade
|
| Selling, General & Admin | 2.49 | 2.21 | 1.36 | 1.5 | 1.32 | 1.31 | Upgrade
|
| Research & Development | 6.69 | 6.52 | 6.74 | 3.98 | 2.6 | 0.71 | Upgrade
|
| Other Operating Expenses | 1.7 | 1.65 | 1.64 | 2.7 | 2.63 | 2 | Upgrade
|
| Operating Expenses | 11.7 | 11.34 | 10.83 | 9.88 | 7.69 | 4.7 | Upgrade
|
| Operating Income | -8.49 | -7.9 | -8.88 | -8.63 | -7.6 | -3.96 | Upgrade
|
| Interest Expense | - | - | -0.01 | -0 | -0.19 | -0.03 | Upgrade
|
| Interest & Investment Income | 0.56 | 0.39 | 0.14 | 0.03 | 0 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | -0.02 | -0 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -7.93 | -7.51 | -8.75 | -8.62 | -7.79 | -3.98 | Upgrade
|
| Asset Writedown | - | - | - | -1.56 | -0.83 | -1.24 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 0.17 | Upgrade
|
| Pretax Income | -7.93 | -7.51 | -8.75 | -10.18 | -8.62 | -5.05 | Upgrade
|
| Earnings From Continuing Operations | -7.93 | -7.51 | -8.75 | -10.18 | -8.62 | -5.05 | Upgrade
|
| Net Income to Company | -7.93 | -7.51 | -8.75 | -10.18 | -8.62 | -5.05 | Upgrade
|
| Net Income | -7.93 | -7.51 | -8.75 | -10.18 | -8.62 | -5.05 | Upgrade
|
| Net Income to Common | -7.93 | -7.51 | -8.75 | -10.18 | -8.62 | -5.05 | Upgrade
|
| Shares Outstanding (Basic) | 1,168 | 1,097 | 941 | 711 | 550 | 331 | Upgrade
|
| Shares Outstanding (Diluted) | 1,168 | 1,097 | 941 | 711 | 550 | 331 | Upgrade
|
| Shares Change (YoY) | 14.71% | 16.55% | 32.32% | 29.45% | 66.10% | 132.61% | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | Upgrade
|
| Free Cash Flow | -6.93 | -7.34 | -7.04 | -6.4 | -6.3 | -3.71 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 86.01% | 30.00% | 75.29% | Upgrade
|
| Operating Margin | -264.40% | -229.61% | -454.69% | -593.40% | -2568.01% | -399.66% | Upgrade
|
| Profit Margin | -246.95% | -218.28% | -448.03% | -699.91% | -2914.23% | -509.99% | Upgrade
|
| Free Cash Flow Margin | -215.75% | -213.45% | -360.80% | -439.99% | -2130.85% | -374.92% | Upgrade
|
| EBITDA | -8.37 | -7.79 | -8.83 | -8.53 | -7.46 | -3.82 | Upgrade
|
| EBITDA Margin | -260.73% | -226.49% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.12 | 0.11 | 0.04 | 0.1 | 0.14 | 0.14 | Upgrade
|
| EBIT | -8.49 | -7.9 | -8.88 | -8.63 | -7.6 | -3.96 | Upgrade
|
| EBIT Margin | -264.40% | -229.61% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.